Biotech | April 22, 2022
Terran Biosciences announces licensing deal with Sanofi
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
An estimated 21 million American women experience BV
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Adds five years of market exclusivity on approval
Subscribe To Our Newsletter & Stay Updated
